Understanding Treatment Strategies and Preferences in Nonmetastatic Castration-Resistant Prostate Cancer From the Japanese Physician Perspective

PURPOSE: Sixteen percent (16%) of patients with castration-resistant prostate cancer (CRPC) show no bone metastasis at diagnosis. However, 33% will become metastatic within 2 years. The goal of treatment in patients with nonmetastatic CRPC (nmCRPC), therefore, is to delay symptomatic metastases with...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Kazuhiro, Grillo, Vince, Chen, Yirong, Singh, Shikha, Ledesma, Dianne Athene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081502/
https://www.ncbi.nlm.nih.gov/pubmed/33617305
http://dx.doi.org/10.1200/GO.20.00358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081502/
https://www.ncbi.nlm.nih.gov/pubmed/33617305
http://dx.doi.org/10.1200/GO.20.00358

Ejemplares similares